Trenon A (Trenbolone Acetate)

02 Details

Trenon A

(Trenbolone Acetate)

 

Trenbolone Acetate; Acetato de trenbolona; RU-1697; Trenbolone, Acétate de; Trenboloni Acetas; Trienbolone Acetate. 17β-Hydroxyestra-4,9,11-trien-3-one acetate. Тренболона Ацетат

 

C20H24O3 = 312.4.

 

CAS — 10161-33-8 (trenbolone); 10161-34-9 (trenbolone acetate).

 

Pharmacopoeias.

USP 31(Trenbolone Acetate). Solution oily transparent color from light yellow to yellow, with characteristic odor. It should be stored at temperatures of 2° to 8°C for optimal storage conditions.

 

Trenon A contains: 100mg

• 100 mg / ml Trenbolone acetate

 

 

Pharmacologic Category

Androgen

Dosing and administration:

 

Deep intramuscular injection.  50-200mg once a week every 2 to 4 weeks.
Dosing: Renal Impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema.

Dosing: Hepatic Impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution.

Use:

 

Trenbolone acetate has been used as an anabolic agent in practice.

 

It is administered through deep intramuscular injection and is used to improve body weight, feed conversion and nitrogen retention 60-90 days. It is used alone or in combination with another hormonally active ingredient.

 

Storage/Stability

 

Store in airtight containers at room temperature.

 

Contraindications

Hypersensitivity to trenbolone, benzyl alcohol or any component of the formulation.

Men with carcinomas of the breast or with known or suspected carcinomas of the prostate; women who are or may become pregnant.

Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

• Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.
• Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.

Disease-related concerns:

• Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.
• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.
• Hepatic impairment: Use with caution in patients with hepatic impairment.

Pregnancy Risk Factor

X

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

 

Pregnancy Considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.

Lactation

Excretion in breast milk unknown/not recommended

Adverse Reactions

Frequency unknown.

Cardiovascular: Edema

Central nervous system: Depression, excitation, insomnia

Dermatologic: Acne (females and prepubertal males)

Also reported in females: Hirsutism, male-pattern baldness

Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes

Also reported in females: Clitoral enlargement, menstrual irregularities

Genitourinary:

Prepubertal males: Increased or persistent erections, penile enlargement

Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited

Hematologic: Prothrombin time increased, suppression of clotting factors

Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy)

Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children)

Renal: Creatinine excretion increased

Metabolism/Transport Effects

 

None known.

 

Drug Interactions

Corticosteroids, Warfarin and Antidiabetic agents.

Test Interactions

 

May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake

Monitoring Parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation)

Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer

Dosage Forms

Injectable solution – 100mg/1ml and 30mg/1ml (contains benzyl alcohol)

Anatomic Therapeutic Chemical (ATC) Classification

• A14AB

Mechanism of Action

 

Anabolic steroid derived from Nandrolone, sharing some properties. Characterized by its androgenic and anti-glucocorticoid activity with the ability to promote growth up to 20% in animal studies.

 

Pharmacodynamics/Kinetics

 

Trenbolone acetate upon entering the circulatory system is rapidly hydrolysed to its free active form, trenbolone (TB0H). In the rat the 173-epimer is the major metabolite.

Metabolism: Hepatic

Elimination: Bile (80%)

Half-life: 2 weeks.